ACTIVE SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS
Clinical trials for ACTIVE SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS explained in plain language.
Never miss a new study
Get alerted when new ACTIVE SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS trials appear
Sign up with your email to follow new studies for ACTIVE SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Can a pill calm the immune attack in MS? a trial looks inside the spinal fluid
Disease control CompletedThis trial tests whether cladribine tablets change key immune cells and nerve damage markers in the spinal fluid of people with relapsing forms of multiple sclerosis. Participants take cladribine as prescribed and undergo up to two lumbar punctures to measure these biomarkers ove…
Matched conditions: ACTIVE SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS
Phase: PHASE4 • Sponsor: Gregory Wu • Aim: Disease control
Last updated Jul 30, 2026 00:00 UTC
-
Italian MS patients on mayzent show promise in slowing disability over 3 years
Disease control CompletedThis study followed 134 adults in Italy with active secondary progressive multiple sclerosis who were prescribed siponimod (Mayzent) as part of their routine care. Over 36 months, researchers measured how many patients experienced a confirmed worsening of disability or cognitive …
Matched conditions: ACTIVE SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS
Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New MS drug combo shows promise in early trial
Disease control CompletedThis study tested an experimental drug called BIIB091, alone or combined with an approved MS drug (diroximel fumarate), in 127 people with relapsing multiple sclerosis. The goal was to check safety and see if it reduces brain inflammation on MRI scans. Participants took pills twi…
Matched conditions: ACTIVE SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS
Phase: PHASE2 • Sponsor: Biogen • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
New study tracks kesimpta side effects in MS patients
Knowledge-focused CompletedThis completed observational study followed 367 people with relapsing-remitting or active secondary progressive multiple sclerosis who were taking Kesimpta for the first time. Researchers tracked side effects and how well the drug worked in everyday use. The goal was to gather re…
Matched conditions: ACTIVE SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS
Sponsor: Novartis Pharmaceuticals • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:00 UTC